A phase III, double-blind, randomized, placebo-controlled, multi-center study evaluating the efficacy and safety of dalcetrapib on lipids, lipoproteins, apolipoproteins and markers of CV risk in patients hospitalized for an acute coronary syndrome (ACS) when treatment is initiated within 1 week after an ACS (dal-ACUTE).

Registry ID

EUCTR2010-022529-14

Source registry

EUCTR

Status

Completed

Phase

PHASE3

Sponsor

F.Hoffmann-La Roche

Start date

2010-12-28

Completion date

2012-03-26

Last update

2026-08-16

Conditions

• Coronary Heart Disease

Summary

-To evaluate the effect of dalcetrapib on high-density lipoprotein C (HDL-C) levels after 4 weeks of treatment when treatment is initiated within one week after an ACS.

Locations

• , , Czechia
• , , Netherlands
• , , UK

Related clinical trials

• Thiamine Intervention and Coronary Artery Bypass Grafting
• Modifiable Risk Factors for Cognitive Dysfunction in Patients With Coronary Heart Disease
• Construction of a Prospective Cohort Database for the Perioperative Period of Cardiac Surgery
• CTCA Prior to Invasive Angiography in Post-Bypass Patients (BYPASS CTCA 2)
• A Study Evaluating the Vascular Healing and Neointimal Transformation at 1 Month After Implantation of BioFreedom™ Drug-coated Stents and the Xience Drug-eluting Stent System in Patients With Acute Coronary Syndrome and High Bleeding Risk Using Optical Coherence Tomography
• A Study on Yiyang Huoluo Decoction in the Treatment of Coronary Heart Disease

View on source registry